U.S. Mrna Therapeutics Market Size & Outlook, 2023-2030
U.S. mrna therapeutics market, 2021-2030 (US$M)
Related Markets
U.S. mrna therapeutics market highlights
- The U.S. mrna therapeutics market generated a revenue of USD 3,948.3 million in 2023 and is expected to reach USD 9,697.8 million by 2030.
- The U.S. market is expected to grow at a CAGR of 13.7% from 2024 to 2030.
- In terms of segment, infectious diseases was the largest revenue generating application in 2023.
- Infectious Diseases is the most lucrative application segment registering the fastest growth during the forecast period.
Mrna therapeutics market data book summary
| Market revenue in 2023 | USD 3,948.3 million |
| Market revenue in 2030 | USD 9,697.8 million |
| Growth rate | 13.7% (CAGR from 2023 to 2030) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Infectious Diseases |
| Historical data | 2021 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Infectious Diseases |
| Key market players worldwide | Moderna Inc, BioNTech SE ADR, CureVac NV Ordinary Shares, Arcturus Therapeutics Holdings Inc, Sanofi SA, GSK PLC, Pfizer Inc, AstraZeneca PLC, Argos Therapeutics, ETHRIS |
Other key industry trends
- In terms of revenue, U.S. accounted for 33.6% of the global mrna therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. mrna therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 2,048.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
MRNA Therapeutics Market Scope
MRNA Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. mrna therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the U.S. mrna therapeutics market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
A large number of market players in the U.S. are engaged in continuous development of advanced mRNA therapeutics for research. Presence of innovators and major market players has resulted in higher product penetration in the country.
Furthermore, presence of a structured environment for usage and approvals of mRNA-based therapeutics & vaccines and local presence of key companies, such as BOC Sciences, Thermo Fisher Scientific, New England Biolabs, and Maravai Life Sciences; and a comprehensive informatics network within the country, are boosting market growth.
For instance, in August 2022, New England Biolabs introduced a novel Fausto virus Capping Enzyme for enzymatic capping of mRNA to support mRNA therapeutic manufacturing requirements. Furthermore, key players in the market are signing deals with government organizations and universities to develop mRNA vaccines for various infectious diseases, such as Ebola.
Reasons to subscribe to U.S. mrna therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. mrna therapeutics market databook
-
Our clientele includes a mix of mrna therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. mrna therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. mrna therapeutics market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. mrna therapeutics market size, by application, 2021-2030 (US$M)
U.S. MRNA Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
